New renin-angiotensin-system (RAS) inhibitor therapy using sacubitril-valsartan (Entresto) is no more likely to cause angioedema than starting out with an ACE inhibitor or angiotensin receptor blocker ...
Patients with heart failure who start taking sacubitril/valsartan (Entresto; Novartis) do not appear to have a greater risk of angioedema than do those who opt for an ACE inhibitor or ARB instead, an ...
Treatment with an angiotensin-converting enzyme (ACE) inhibitor/angiotensin receptor blocker and sodium-glucose cotransporter-2 (SGLT2) inhibitor combination demonstrated better outcomes in kidney ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback